Journal des complications et de la médecine du diabète

Domperidone is a dopamine receptor antagonist that exerts its effects primarily in the gastrointestinal tract. It is widely used to manage gastrointestinal motility disorders such as gastroparesis and nausea associated with various conditions, including chemotherapy and Parkinson's disease. This comprehensive review explores the mechanism of action of domperidone, its pharmacokinetics, clinical uses across different patient populations, efficacy, safety profile, and current controversies surrounding its use.

Neuropathy encompasses various conditions caused by damage to peripheral nerves, leading to sensory, motor, and autonomic dysfunction. This article delves into the complexities of neuropathy, covering its causes, diverse clinical manifestations, and current treatment options. Understanding these intricacies enables healthcare providers and patients to tackle diagnostic challenges, optimize management, and enhance quality of life. By shedding light on the multifaceted nature of neuropathic conditions, the article aims to promote better patient care and improved outcomes in managing this often debilitating group of disorders.

Insulin, a crucial hormone produced by the pancreas, plays an essential role in regulating blood sugar levels, ensuring that the body functions optimally. This paper delves into the science behind how insulin works, exploring its production, secretion, and action at the cellular level. Key mechanisms, including the insulin signaling pathway, glucose uptake, and storage processes, are discussed in detail. Furthermore, the paper examines conditions related to insulin dysfunction, such as diabetes mellitus, and the importance of insulin therapy in managing these conditions.

Erythromycin, a widely used macrolide antibiotic, is effective against various bacterial infections and also serves as a prokinetic agent for gastrointestinal disorders. Despite its efficacy, erythromycin is known for significant drug interactions due to its ability to inhibit the cytochrome P450 (CYP) enzyme system, particularly CYP3A4. These interactions can lead to altered pharmacokinetics of co-administered drugs, resulting in either reduced therapeutic efficacy or increased toxicity. This comprehensive review explores the pharmacokinetics and pharmacodynamics of erythromycin, identifies major drug interactions, and discusses the clinical implications of these interactions. Understanding these interactions is crucial for optimizing therapeutic outcomes and minimizing adverse effects.